A significant proportion of patients with Crohn’s disease (CD) will develop complications requiring surgery. However, surgery is not a cure for CD, and a majority will develop disease recurrence. Multiple studies have shown that infliximab and adalimumab can reduce rates of post-surgical recurrence, particularly with a preventative approach. Anecdotally, we see many CD patients returning to care after a surgical resection with recurrent symptoms that could have potentially been prevented with post-operative biologic therapy.